ADAR1 (A-to-I) is also advancing: multiple preclinical efforts now report small-molecule ADAR1 inhibitors that boost MDA5-dependent IFN signaling and show antitumor activity, while orthogonal data in prostate cancer describe ZYS-1 with in vivo efficacy—collectively arguing that pharmacologic ADAR1 blockade is becoming feasible, though clinical translation is still ahead (149). This evidence concerns the gene ADAR and prostate carcinoma.